IGHE and asthma: Omalizumab (Xolair), is an anti-human IgE monoclonal antibody (mAb) commercialized in the market worldwide as an add-on therapy for patients with severe allergic asthma and medicaments with inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) (Global Initiative for Asthma, 2022).